Pfizer to buy Metsera in deal worth up to $10 billion

Why was it worth it to you to spend that additional money, Albert, and why should it be worth it to your shareholders to own this company. >> This is probably one of the most exciting advanced portfolios in this very fast growing market, the obesity. We've looked everything in the US, in Europe, in China, everywhere.And uh we came to the conclusion that this was the one that in our hands can develop significant value. And we did it. What is it about it in your hands that you believe will will uh create sign ...